FLT3+ Blasts (AML)
Biopharma: This test is available for use in clinical trials or research purposes only.
Expected Turnaround Time
2 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
Detection of FLT3 on blasts. Panel inclusive of icTdT, icMPO, CD64, CD10, CD19, icCD3, icCD79a, CD34, CD45, and FLT3.
Specimen Requirements
Specimen Requirements
Bone Marrow Aspirate: 2 mL (minimum of 0.5 mL with 107 cells), NaHep preferred (EDTA accepted)
Specimen Stability
Specimen stable for 48 hours at 4°C.
Storage Requirements
2°C to 8°C
Shipping Conditions
Refrigerated
Shipping Recommendations
REFRIGERATED, Use a refrigerated (NOT FROZEN) gel pack in the shipment to protect from extreme temperatures. Separate gel pack from specimen
Specimen Rejection Criteria
Specimens stored at incorrect temperature; Non-viable specimens; Specimens in inappropriate anticoagulant; Too few cells; Hemolysis; Specimen clotted
Test Details
Synonyms
Receptor-type tyrosine-protein kinase FLT3, EC:2.7.10.1, FL cytokine receptor, Fetal liver kinase-2, FLK-2, Fms-like tyrosine kinase 3, FLT-3, Stem cell tyrosine kinase 1, STK-1, CD135
Test Method
Flow cytometry
Methodology Category
Flow Cytometry
Regulatory Status
RUO
Associations
AML